These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25386854)

  • 1. Serum uric acid and nigral iron deposition in Parkinson's disease: a pilot study.
    Kim TH; Lee JH
    PLoS One; 2014; 9(11):e112512. PubMed ID: 25386854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nigral iron deposition occurs across motor phenotypes of Parkinson's disease.
    Jin L; Wang J; Jin H; Fei G; Zhang Y; Chen W; Zhao L; Zhao N; Sun X; Zeng M; Zhong C
    Eur J Neurol; 2012 Jul; 19(7):969-76. PubMed ID: 22288465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron deposition in Parkinson's disease by quantitative susceptibility mapping.
    Chen Q; Chen Y; Zhang Y; Wang F; Yu H; Zhang C; Jiang Z; Luo W
    BMC Neurosci; 2019 May; 20(1):23. PubMed ID: 31117957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study.
    Zhang J; Zhang Y; Wang J; Cai P; Luo C; Qian Z; Dai Y; Feng H
    Brain Res; 2010 May; 1330():124-30. PubMed ID: 20303339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping.
    He N; Ling H; Ding B; Huang J; Zhang Y; Zhang Z; Liu C; Chen K; Yan F
    Hum Brain Mapp; 2015 Nov; 36(11):4407-20. PubMed ID: 26249218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility.
    Martin-Bastida A; Lao-Kaim NP; Loane C; Politis M; Roussakis AA; Valle-Guzman N; Kefalopoulou Z; Paul-Visse G; Widner H; Xing Y; Schwarz ST; Auer DP; Foltynie T; Barker RA; Piccini P
    Eur J Neurol; 2017 Feb; 24(2):357-365. PubMed ID: 27982501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation effect of substantia nigra iron deposition and functional connectivity on putamen glucose metabolism in Parkinson's disease.
    Zang Z; Song T; Li J; Yan S; Nie B; Mei S; Ma J; Yang Y; Shan B; Zhang Y; Lu J
    Hum Brain Mapp; 2022 Aug; 43(12):3735-3744. PubMed ID: 35471638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.
    Du G; Lewis MM; Shaffer ML; Chen H; Yang QX; Mailman RB; Huang X
    PLoS One; 2012; 7(4):e35397. PubMed ID: 22530017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of freezing of gait with nigral iron accumulation in patients with Parkinson's disease.
    Naduthota RM; Honnedevasthana AA; Lenka A; Saini J; Geethanath S; Bharath RD; Christopher R; Yadav R; Gupta AK; Pal PK
    J Neurol Sci; 2017 Nov; 382():61-65. PubMed ID: 29111022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of cerebral iron content in patients with Parkinson's disease by the susceptibility-weighted MRI.
    Wu SF; Zhu ZF; Kong Y; Zhang HP; Zhou GQ; Jiang QT; Meng XP
    Eur Rev Med Pharmacol Sci; 2014; 18(18):2605-8. PubMed ID: 25317792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Susceptibility Mapping in Parkinson's Disease.
    Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
    PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic impacts on nigral iron deposition in Parkinson's disease: A preliminary quantitative susceptibility mapping study.
    Wu J; Guo T; Zhou C; Bai X; Liu X; Gu L; Xuan M; Gu Q; Huang P; Song Z; Zhang B; Xu X; Zhang M; Guan X
    CNS Neurosci Ther; 2023 Jul; 29(7):1776-1784. PubMed ID: 36852447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry.
    Pyatigorskaya N; Sharman M; Corvol JC; Valabregue R; Yahia-Cherif L; Poupon F; Cormier-Dequaire F; Siebner H; Klebe S; Vidailhet M; Brice A; Lehéricy S
    Mov Disord; 2015 Jul; 30(8):1077-84. PubMed ID: 26011561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower Serum Bilirubin and Uric Acid Concentrations in Patients with Parkinson's Disease in China.
    Qin XL; Zhang QS; Sun L; Hao MW; Hu ZT
    Cell Biochem Biophys; 2015 May; 72(1):49-56. PubMed ID: 25449297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects.
    Bartzokis G; Cummings JL; Markham CH; Marmarelis PZ; Treciokas LJ; Tishler TA; Marder SR; Mintz J
    Magn Reson Imaging; 1999 Feb; 17(2):213-22. PubMed ID: 10215476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages.
    Rossi ME; Ruottinen H; Saunamäki T; Elovaara I; Dastidar P
    Acad Radiol; 2014 Jan; 21(1):64-71. PubMed ID: 24331266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nigral Iron Deposition Influences Disease Severity by Modulating the Effect of Parkinson's Disease on Brain Networks.
    Wen J; Guo T; Wu J; Bai X; Zhou C; Wu H; Liu X; Chen J; Cao Z; Gu L; Pu J; Zhang B; Zhang M; Guan X; Xu X
    J Parkinsons Dis; 2022; 12(8):2479-2492. PubMed ID: 36336939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.